Phage‐Antibiotic Combinations for Pseudomonas : Successes in the Clinic and In Vitro Tenuously Connected
Комбинации фагов и антибиотиков против Pseudomonas: успехи в клинике и их слабая связь с результатами in vitro
2025-07-01
SCID: 54.1/sxpr58pd
Discuss with AI
Pseudomonas aeruginosaantimicrobial resistancebiofilm infectionsphage-antibiotic combinationsphage-antibiotic interaction metrics
Figures from the paper
Abstract (AI)
Antimicrobial resistance challenges researchers to innovate strategies to enhance the effectiveness of our existing antibiotics. Bacteriophage (phage, bacterial virus)-antibiotic combinations present a promising synergistic approach, particularly for drug-resistant infections such as those caused by Pseudomonas aeruginosa. This approach offers many advantages: enhanced bacterial killing (both planktonic and biofilm), eliminating persister cells, re-sensitization to drugs, and inhibiting resistance spread by targeting plasmids encoding resistant genes. Interestingly, even phages traditionally excluded from therapy - those capable of entering dormancy in the bacterial host - exhibit unique, potent synergy with antibiotics. Despite these clear in vitro benefits and the comparatively strong performance of phage antibiotic combinations in the clinic, translating in vitro efficacy to patient outcomes remain challenging. The lack of standardized metrics for measuring phage-antibiotic interaction complicates cross-study comparisons. In many instances, it is also difficult to translate these in vitro findings to clinically relevant metrics - for example, increased progeny size in vitro is unlikely to contribute meaningfully to treatment success. Addressing these gaps will allow us to fully harness the potential of phage-antibiotic combinations and bridge the disconnect between in vitro results and clinical success.
Key Findings
1
Clinical performance of phage–antibiotic combinations appears comparatively strong, but in vitro efficacy remains tenuously connected to patient outcomes.
2
Lack of standardized interaction metrics and clinically relevant endpoints hinders cross-study comparison and translation of in vitro findings.
3
Phages capable of entering host dormancy, traditionally excluded from therapy, can nevertheless display potent synergy with antibiotics.
4
Phage–antibiotic combinations can enhance killing of Pseudomonas aeruginosa, including planktonic bacteria, biofilms, and persister cells.
5
These combinations may re-sensitize resistant bacteria to antibiotics and limit resistance dissemination by targeting plasmids carrying resistance genes.
Research Object
Phage-antibiotic combinations for treating drug-resistant Pseudomonas aeruginosa infections
Research Subject
Their synergistic antimicrobial efficacy and the translation of in vitro interaction metrics into clinically relevant treatment outcomes
Publication Details
Publication Date
2025-07-01
Journal
Publisher
ISSN
Cited by
16
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest